Dr Anthony Filippis will serve as Neurotech’s managing director from February 1, 2025. Pic: Getty Images.
Dr Anthony Filippis to helm Neurotech as it advances its NTI164 strategy in 2025
Health & Biotech
share
- Neurotech appoints biotech veteran Dr Anthony Filippis as its managing director
- Filippis has deep understanding of industry and a strong track record of partnering success and capital markets expertise
- Experience will help company execute its NTI164 strategy in 2025
Special Report: Neurotech has appointed Dr Anthony Filippis as its managing director to steer the company as it progresses clinical testing of its broad-spectrum cannabinoid drug NTI164.
Filippis is currently the chief operating officer of Percheron Therapeutics (ASX:PER), which has an ongoing Phase IIb clinical trial in the rare paediatric disease, Duchenne muscular dystrophy.
He has over 25 years’ biotech experience and is an internationally proven senior business leader with a deep understanding and knowledge of the biotech industry and capital markets.
His transaction-focus is reflected in the several partnering and M&A transactions with pharmaceutical and biotech companies that he has led and completed.
These include raising capital and closing deals with blue-chip companies like Siemens Healthineers, AstraZeneca, Schering Plough and Meditech.
Prior to joining PER in November 2022, Dr Filippis was chief executive officer and managing director of Neurosciences Victoria for five and half years and before that chief executive officer of neuroscience drug development company Drawbridge Pharmaceuticals for four years.
Life sciences expertise
“Following an extensive search of potential candidates for the role, we are delighted that someone of the calibre of Anthony has agreed to join the company as managing director and CEO, commencing 1 February 2025,” chairman Mark Davies said.
He added that he will bring his significant experience across the life sciences sector – with an outstanding track record of partnering success and capital markets expertise – to Neurotech International (ASX:NTI).
Dr Filippis said he was delighted to join the company at this important stage of its development.
“With an exciting pipeline and an excellent team of clinical collaborators, I look forward to working with the board and the team to bring NTI164 forward to provide new treatment options for patients.”
NTI164 has shown to positively modify immune cell function and address gene translation dysregulation, improving the overall health and functional outcomes of children, when used during clinical trials to treat paediatric neurological disorders.
Notably, certain important dysregulated pathways associated with immune function and gene translation, including MECP2 – the defective gene that causes Rett Syndrome, were significantly reversed with NTI164.
It has also shown significant clinical benefits in the Phase 1/2 clinical trial for the treatment of Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS).
The use of NTI164 to treat Rett Syndrome is currently the subject of a request with the US Food and Drug Administration for orphan drug designation, which qualifies sponsors for incentives including tax credits for qualified clinical trials, exemption from user fees and a potential seven years of market exclusivity after approval.
This article was developed in collaboration with Neurotech International, a Stockhead advertiser at the time of publishing.
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
